SYNTOCINON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNTOCINON is a small-molecule injectable medication approved in 1980 by Novartis. The specific indication and mechanism of action are not disclosed in available data, but its long market tenure suggests established clinical utility. This is a legacy product with approaching loss of exclusivity.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), suggesting defensive commercial strategies and potential team downsizing or redeployment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYNTOCINON offers 17 active job opportunities primarily in management, senior specialist, and leadership roles across R&D, Clinical, Commercial, and Regulatory Affairs. Working on this product provides exposure to mature product lifecycle management, competitive defense strategies, and potential transition into generics or adjacent therapeutic areas.
ManagerDirector
Worked on SYNTOCINON at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.